EP1202971A2 - Arzneimittel, welche 4-chinolonen enthalten zur behandlung von krebs - Google Patents

Arzneimittel, welche 4-chinolonen enthalten zur behandlung von krebs

Info

Publication number
EP1202971A2
EP1202971A2 EP00958676A EP00958676A EP1202971A2 EP 1202971 A2 EP1202971 A2 EP 1202971A2 EP 00958676 A EP00958676 A EP 00958676A EP 00958676 A EP00958676 A EP 00958676A EP 1202971 A2 EP1202971 A2 EP 1202971A2
Authority
EP
European Patent Office
Prior art keywords
group
chosen
alkyl
phenyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00958676A
Other languages
English (en)
French (fr)
Inventor
Benoít JOSEPH
Francis Darro
Gérald Guillaumet
Robert Kiss
Armand Frydman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cephalon France SAS
Original Assignee
Laboratoire L Lafon SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoire L Lafon SA filed Critical Laboratoire L Lafon SA
Publication of EP1202971A2 publication Critical patent/EP1202971A2/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4

Definitions

  • compositions comprising 4-quinolones
  • the present invention relates to pharmaceutical compositions comprising 4-quinolones or derived compounds.
  • Cancer is a disorder of the somatic genes in which genetic dysfunctions are amplified as the tumor process progresses from the precancerous lesion to that of malignant transformation, the cancerous tumor becoming metastatic and often resistant to drugs. cytotoxic.
  • topoisomerase I inhibitors derived from camptothecin (topotecan and irinotecan), vinorelbine (new alkaloid from periwinkle), gemeitabine (new cytotoxic antimetabolic) , raltitrexed (thymidylate synthetase inhibitor) and miltefosine (first representative of the alkyl-lysophospholipid family).
  • camptothecin topotecan and irinotecan
  • vinorelbine new alkaloid from periwinkle
  • gemeitabine new cytotoxic antimetabolic
  • raltitrexed thymidylate synthetase inhibitor
  • miltefosine first representative of the alkyl-lysophospholipid family.
  • a first approach is that of the prevention or treatment of “multidrug-resistant” cancers (MDR) by the use of substances inhibiting or causing the reversibility of MDR resistance associated or not with the expression of the membrane transporter of glycoprotein- P.
  • MDR multidrug-resistant cancers
  • the inventors are interested in a different approach.
  • the objective sought was to make the population of tumor cells more sensitive to reference anticancer treatments in order to achieve a double benefit:
  • compositions capable of inducing a very significant increase in the cytotoxic activity of proven anticancer drugs.
  • the inventors are interested in a particular group of original derivatives of the family of 3-aryl-4-quinolones. These compositions have the capacity either to stimulate the recruitment of clonogenic cells within the tumor making it more sensitive to conventional treatment with cytotoxic agents, or to inhibit the proliferation of clonogenic cells, thus contributing to the regression of the tumor. .
  • a subject of the present invention is therefore the use, in the treatment of cancers with at least one antitumor chosen from cytotoxic agents, of a compound having an activity on the proliferation of clonogenic cells in tumors, but devoid of antitumor activity intrinsic (allowing therapeutic use) and chosen from the compounds of formulas:
  • R is chosen from H, OH, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 alkoxy, phenyl or a phenyl group 1 to 3 times substituted by groups chosen from H, OH, a group - OCOR 7 , R 7 being a C1-C4 alkyl group, a group -O-S0 2 -R ' 7 , R' 7 being a C1-C4 alkyl group or a group CF 3 , and a group -NR 16 R ⁇ 7 , Rie and R 17 being chosen independently of one another from hydrogen, (C1-C4) alkyl, C2-C4 alkenyl, phenyl (C1-C4) alkyl, a phenyl alkyl ( C1 -C4) 1 to 3 times substituted on the alkyl group by groups chosen from H, OH and alkoxy, in C1-C4, or a dimethylaminoalkyl group (C1-
  • R 2 , R 3 and R 4 are chosen independently of one another from H, OH, a C1-C4 alkyl group, a C1-C4 alkoxy group, an -OCO-R 7 group , and a group derived from a ose, at least one of the substituents R 2 , R 3 or R 4 being other than H, and R 2 and R 3 can together form a methylenedioxy group,
  • R 5 is a phenyl group or a phenyl group 1 to 3 times substituted by groups chosen from H, OH, a C1-C4 alkoxy group, a -OCOR 7 group, a phenyl (C1-C4 alkoxy) group, a group -O-SO 2 -R ' 7 , R' 7 being a C1-C40U alkyl group, a CF 3 group, a benzylamino group and a group derived from a ose,
  • R 6 is chosen from H, a C1-C4 alkyl group, C2-C4 alkenyl, a group - CO-R 8 and a group -AR 9 ,
  • R 6a is chosen from a C1-C4 alkyl group, C-2-C4 alkenyl, a group -
  • A being a C1-C4 alkylene group
  • R 9 being chosen from 5 or 6-membered heterocyclic groups having. 1 to 4 heteroatoms chosen from oxygen, sulfur and nitrogen, groups CN, hydroxy -COOR 10 , -CONRuR ⁇ , a group -NR 13 R 14 , a group -COR 15 , and OSO2RI6.
  • R ⁇ and R 15 being independently chosen from a hydrogen atom, a C1-C4 alkyl group and a phenyl (C1-C4 alkyl) group,
  • R 16 being chosen from a phenyl group and an alkyl (C-
  • Cytotoxic agents can be used at their usual dose and, in this case, their effectiveness is improved, or at lower doses given the increase in their antitumor efficacy, to reduce the severity of side effects (e.g. leukopenia, nausea, vomiting, ...) almost constantly encountered.
  • the subject of the present invention is also a composition having an activity on the proliferation of clonogenic cells in tumors by interfering with the generation of clonogenic cells, either by stimulating proliferation and recruitment, or by inhibiting proliferation, and which comprises a effective amount of a compound of formulas:
  • R T is chosen from H, OH, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 alkoxy, phenyl or a phenyl group 1 to 3 times substituted by groups chosen from H, OH , a group -OCOR 7 , R 7 being a C1-C4 alkyl group, a group
  • R' 7 being a C1-C4 alkyl group or a CF 3 group, and a group -
  • NR 16 R 17 , R 16 and R 17 being chosen independently of one another from hydrogen, C1-C4 alkyl, C2-C4 alkenyl, phenyl (C1-C4) alkyl, a phenyl group (C1-C4) alkyl 1 to 3 times substituted on the alkyl group by groups chosen from H,
  • R 2 , R 3 and R 4 are chosen independently of one another from H, OH, a C1-C4 alkyl group, a C1-C4 alkoxy group, an -OCO-R 7 group , and a group derived from a dare, R 2 and R 3 can together form a methylenedioxy group,
  • R 5 is a phenyl group or a phenyl group 1 to 3 times substituted by groups chosen from H, OH, a C1-C4 alkoxy group, a -OCOR 7 group, a phenyl (C1-C4 alkoxy) group, a group -O-SO 2 -R ' 7 , R' 7 being a C1-C40U alkyl group, a CF 3 group, a benzylamino group and a group derived from a ose,
  • R 6 is chosen from H, a C1-C4 alkyl group, (C2-C4) alkenyl, a group -CO-R 8 and a group -AR 9
  • R 6a is chosen from a C1-C4 alkyl group, C2-C4 alkenyl, a group -
  • R 8 being a C1-C4 alkyl group
  • A being a C1-C4 alkylene group
  • R 9 being chosen from 5 or 6-membered heterocyclic groups having 1 to 4 heteroatoms chosen from oxygen, sulfur and nitrogen, groups CN, hydroxy, -COOR 10 , -CONRuR, a group -NR 13 R 14 , a group -COR 15 , and -OS ⁇ 2Rl6
  • R 14 and R 15 are independently selected from a hydrogen atom, an alkyl group C1-C4 and phenyl (C1-C4),
  • R16 being chosen from a phenyl group and an alkyl (C ⁇ -C-4) phenyl group
  • R and R 6 can also form together a group -CO-CH 2 -CH 2 -.
  • the present invention also relates to new compounds, namely compounds of formulas:
  • R ⁇ is chosen from H, OH, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 alkoxy, phenyl or a phenyl group 1 to 3 times substituted by groups chosen from H, OH , a group -OCOR 7 , R 7 being a C1-C4 alkyl group, a group -0-SO 2 -R ' 7 , R' 7 being a C1-C4 alkyl group or a group CF 3 , and a group - NR 16 R 17 , R 16 and R 17 being chosen independently of one another from hydrogen, C1-C4 alkyl, C2-C4 alkenyl, phenyl (C1-C4) alkyl, a group phenyl alkyl (C1-C4) 1 to 3 times substituted on the alkyl group by groups chosen from H, OH and C- ⁇ -C-4 alkoxy, or a dimethylaminoalkyl group (C1
  • R 2 , R 3 and R are chosen independently of one another from H, OH, a C1-C4 alkyl group, a C1-C4 alkoxy group, an -OCO-R 7 group , and a derivative group a dare, R 2 and R 3 which can together form a methylenedioxy group
  • R 5 is a phenyl group or a phenyl group 1 to 3 times substituted by groups chosen from H, OH, a C ⁇ -C4 alkoxy group, a group -OCOR 7 , a phenyl group (C1-C4 alkoxy), a group -O-SO 2 -R ' 7l R' 7 being a C1-C40U alkyl group, a CF 3 group, a benzylamino group and a group derived from an ose
  • R 6 is chosen from H, a C1 alkyl group -C4, (C2-C4) alkenyl, a group -CO
  • R 6a is chosen from a C1-C4 alkyl group, (C2-C4) alkenyl, a group - CO-R 8 and a group -AR 9 ,
  • R 8 being a C1-C4 alkyl group, A being a C1-C4 alkylene group,
  • R 9 being chosen from 5 or 6-membered heterocyclic groups having 1 to 4 heteroatoms chosen from oxygen, sulfur and nitrogen, groups CN, hydroxy, -COOR 10 , -CONRnR 12 , a group -NR 13 R, a group -COR 15 , and -OSO2R16
  • R10, R ⁇ > R ⁇ 2 , Ri3 > RM and R 15 being independently chosen from a hydrogen atom, a C1-C4 alkyl group and a phenyl (C1-C4 alkyl) group,
  • R 16 being chosen from a phenyl group and an alkyl (C ⁇ -C4) phenyl group, R 4 and R 6 can also form together a group -CO-CH 2 -CH 2 -. excluding compounds where:
  • a particular group of compounds is that consisting of the compounds of formulas I or la according to which: R 1 is chosen from H, OH, C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 1 -C 4 alkoxy, phenyl or a phenyl group 1 to 3 times substituted with groups chosen from H, OH , a group -OCOR7, R7 being a C1-C4 alkyl group, a group -O-SO2- R'7, R'7 being a C1-C4 alkyl group or a group CF3, and a benzylamino group, R2.
  • R3 and R4 are chosen independently of one another from H, OH, a C1-C4 alkyl group, a C1-C4 alkoxy group, a -OCO-R7 group, and a group derived from an ose and R2 and R3 can together form a methylenedioxy group,
  • R5 is a phenyl group or a phenyl group 1 to 3 times substituted by groups chosen from H, OH, a C1-C4 alkoxy group, a -OCOR7 group, a phenyl (C1-C4 alkoxy) group, a group - O-S ⁇ 2-R'7, R'7 being a C1-C4 alkyl group or a CF3 group, a benzylamino group and a group derived from a ose,
  • R6 is chosen from H, a C1-C4 alkyl group, a -CO-Rs group and a -A-Rg group,
  • R ⁇ a is chosen from a C1-C4 alkyl group, a -CO-Rs group and an -A-Rg group,
  • R8 being a C1-C4 alkyl group, A being a C1-C4 alkylene group,
  • Rg being chosen from 5 or 6-membered heterocyclic groups having 1 to 4 heteroatoms chosen from oxygen, sulfur and nitrogen, the group CN, a group - COOR10, -CONR1 1 R12, a group -NR13R-14 , and a group -COR15,
  • R10. R11. R12- R 13- R14 and R15 being independently chosen from a hydrogen atom, a C1-C4 alkyl group and a phenyl (C1-C4 alkyl) group, R 4 and R 6 can also together form a group - CO-CH 2 -CH 2 -.
  • Another particular group of compounds is that consisting of the compounds of formulas I or la in which:
  • R 5 is a phenyl, 4-methoxyphenyl, 2,4-dimethoxyphenyl and 2,5-dimethoxyphenyl group,
  • Another particular group of compounds is that consisting of the compounds of formulas I or la in which:
  • R 1 is chosen from C 1 -C 4 alkyl, C 2 -C 4 alkenyl, phenyl or a phenyl group 1 to 3 times substituted by groups chosen from H, OH, a group -OCOR 7 , R 7 being a group C1-C4 alkyl, a group -O-SO 2 -R ' 7 , R' 7 being a C1-C40U alkyl group a group CF 3 , and a group -NR 16 R ⁇ 7 , R ⁇ 6 and R 17 being chosen independently of one another among hydrogen, C1-C4 alkyl, C2-C4 alkenyl, phenyl (C1-C4) alkyl, a phenyl (C1-C4) alkyl group 1 to 3 times substituted on the alkyl group with groups chosen from H, OH and C ⁇ -C-4 alkoxy, or a dimethylaminoalkyl group (C1-C4), or forming together and, with the nitrogen
  • Another particular group of compounds is that consisting of the compounds of formulas I or la in which:
  • R2 > R3 and R4 are chosen from a hydrogen atom and a C ⁇ -C4 alkoxy group.
  • a group derived from an ose denotes a group which forms, with the remainder of the molecule, a heteroside.
  • these heterosides are capable of giving a compound of formula I or la with a hydroxy group and a ose.
  • the dares can be in particular monosaccharide (glucose, rhamnose) or disaccharide (for example rutinose).
  • the compounds of formulas (I) and (la) can be administered at the start of chemotherapeutic treatments either at once or over several days at the start of these treatments (for example for 5 to 7 days) and, depending on the chemotherapy protocol, at the start of each treatment cycle (for example for 2 to 5 days) during each course.
  • the compounds of formulas (I) and (la) are advantageously administered by infusion (generally in 1 to 3 hours) at doses of 1 to 50 mg / kg / day or 40 to 2000 mg / n Vday.
  • the compounds of formulas (I) and (la) must be administered in such a way that the tissue concentrations obtained are as high as possible. consider.
  • the intravenous route is to be preferred using: - ready-to-use infusion solutions (bags, bottles, etc.) intended to be administered as such by intravenous infusion using an infusion line and at the recommended rate:
  • lyocs for oral or perlingual absorption
  • instant or delayed release tablets for oral solutions, suspensions, granules, capsules, etc.
  • Cytotoxic agents can be chosen from: i) intercalating agents, in particular doxorubicin (Adriamycin), daunorubicin, epirubicin, idarubicin, zorubicin, aclarubicin, pirarubicin, acridin, mitoxanthrone, l actinomycin D, eptilinium acetate; ii) alkylating agents chosen from platinum derivatives (cisplatin, carboplatin, oxaliplatin); iii) a compound chosen from other groups of alkylating agents:
  • BCNU carmustine
  • CCNU lamelonine
  • fotemustine fotemustine
  • streptozotocin
  • - ethyleneimines altretamine, triethylene-thiophosphoramide, iv) a compound chosen from other groups of anti-metabolic agents:
  • - antipurics purinethol, thioguanine, pentostatin, cladribine
  • vinca-alkaloids disorganizing the mitotic spindle: vincristine, vinblastine, vinguerine, navelbine
  • paclitaxel agents blocking the depolymerization of the mitotic spindle: paclitaxel, docetaxel - agents inducing DNA breaks by inhibition of topoisomerase II: etoposide, teniposide
  • - topoisomerase I inhibitors inducing DNA breaks topotecan, irinotecan, vi) a splitting agent, fragmenting DNA, such as bleomycin, vii) one of the following compounds; plicamycin, L-asparaginase, mitoguazone, dacarbazine, viii) an anti-cancer progestin steroid: medroxy-progesterone, megestrol, ix) an anti-cancer estrogenic steroid: diethylstilbestrol; tetrasodium fosfestrol, x) an anti-estrogen: tamoxifen, droloxifene, raloxifene, amino-gluthetimide, xi) a steroid antiandrogen (ex cyproterone) or a nonsteroidal antiandrogen (flutamide, nilutamide).
  • a splitting agent fragmenting DNA, such as bleomycin
  • the compounds of formula (I) and (la) can be associated with all the treatments with the major cytotoxic agents used in polychemotherapies of solid tumors such as:
  • - anti-metabolites such as methotrexate, 5-FU, Ara-C, capecitabine
  • vinca alkaloids vincristine, vinblastine, vindesine, navelbine
  • taxoids paclitaxel, docetaxel
  • epipodophyllotoxin derivatives etoposide, teniposide
  • topoisomerase I inhibitors topotecan, irinotecan.
  • the compounds of formula (I) and (la) can be combined with the treatments by the major cytotoxic agents used in oncohematology for the treatment of blood cancers:
  • cyclophosphamide mechlorethamine, chlorambucil, melphalan, ifosfamide, etoposide, doxorubicin, daunorubicin;
  • - acute leukemias methotrexate, 6-mercaptopurine, cytarabine, vinblastine, vincristine, doxorubicin, daunorubicin, L-asparaginase
  • - non-Hodgkin's malignant lymphomas mechlorethamine, chlorambucil, cyclophosphamide, melphalan, ifosfamide, methotrexate, cytarabine, vinblastine, vincristine, etoposide, doxorubicin, daunorubicin, carmustine, lomustine, cisplatin
  • chronic lymphoid leukemia mechlorethamine, chlorambucil, cyclophosphamide, melphalan, ifosfamide.
  • the alkoxy groups can be converted to hydroxy groups according to known methods.
  • the hydroxy groups can be transformed into an ester or a sulfonate according to known methods, the sulfonates which can, in turn, be converted into alkenyl, phenyl or substituted phenyl groups and - NR 16 Ri7 according to known methods.
  • the compound 10 (1.20 g, 3.66 mmol) is added quickly and this quickly to a solution of biphenyl (1.52 g) and diphenyl ether (11.60 g) heated to 250 ° vs. After 10 min, the heating is stopped. Upon cooling, the final product 11 precipitates from the reaction medium. The crude product is collected by filtration and then rinsed with petroleum ether. The latter is taken up in ethanol. The suspension is heated to reflux with stirring. After cooling and filtration, 753 mg (73%) of compound 11 are obtained in the form of white crystals.
  • reaction mixture is diluted with toluene (10 ml) and then acidified with 10% HCl. After extraction, the organic phase obtained is dried over MgSO 4 and then evaporated under reduced pressure. The residue is purified by chromatography on a silica column (eluent: CH 2 CI 2 ) to give 1.92 g (60%) of compound 13 in the form of an oil which crystallizes from methanol.
  • the compound 20 (1.30 g, 3.97 mmol) is added in small portions and this quickly to a solution of biphenyl (1.36 g) and diphenyl ether (10.40 g) heated to 250 ° C. After 10 min, the heating is stopped. During the cooling of the reaction medium, the product precipitates. 972 mg (87%) of compound 21 are thus collected by filtration in the form of white crystals.
  • EXAMPLE 15 7-Methoxy-3- (4-methoxyphenyl) -1,4-dihydro-4-quinolinone (compound 26) -CRL8358 and 5-Methoxy-3- (4-methoxyphenyl) -1, 4-dihydro-4 -quinolinone (compound 27) - CRL8491 a) (Z) -3- (3-Methoxyanilino) -2- (4-methoxyphenyl) -2-ethyl propenoate (25)
  • the compound 28 (1.10 g, 3.08 mmol) is added in small portions and this quickly to a solution of biphenyl (3.00 g) and diphenyl ether (7.51 g) heated to 250 ° vs. After 10 min, the heating is stopped. During cooling, the quinolone 29 precipitates in the reaction medium. This product is collected by filtration and then rinsed with petroleum ether. After drying, 680 mg (71%) of compound 29 are obtained in the form of white crystals.
  • the compound 30 (900 mg, 2.52 mmol) is added in small portions and this quickly to a solution of biphenyl (1.18 g) and diphenyl ether (8.05 g) heated to 250 ° vs. After 10 min, the heating is stopped. Upon cooling, the final product precipitates from the reaction medium. This product is collected by filtration and then rinsed thoroughly with petroleum ether. After drying,
  • EXAMPLE 33 ⁇ / - [3- (Dimethylamino) ethyl] -5,7-dimethoxy-3- (4-methoxyphenyl) -1,4-dihydro-4-quinolinone (compound 54) - CRL 8350 and ⁇ - ⁇ 2 - [5,7-Dimethoxy-3- (4-methoxyphenyl) - 4-quinolyl] oxy ⁇ ethyl- ⁇ t, ⁇ / -dimethylamine (55) -CRL8505 a) ⁇ / - [3- (Dimethylamino) ethyl] -5 , 7-dimethoxy-3- (4-methoxyphenyl) -1,4-dihydro-4-quinolinone (compound 54) - CRL 8350
  • EXAMPLE 36 2- [5,8-Dimethoxy-3- (4-methoxyphenyl) -4-oxo-1, 4-dihydro-1 -quinolinyl] ethyl acetate (compound 58) - CRL 8381 and 2 - ⁇ [ 5,8-Dimethoxy-3- (4-methoxyphenyl) -4-quinolinyl] oxy ⁇ ethyl acetate (compound 59) -CRL 8506 a) 2- [5,8-Dimethoxy-3- (4-methoxyphenyl) - 4-oxo-1, 4-dihydro-1 -quinolinyl] ethyl acetate (compound 58) - CRL 8381
  • reaction solution is extracted with ethyl acetate (twice).
  • organic phase obtained is dried over MgSO 4 , then evaporated under reduced pressure.
  • residue obtained is purified by chromatography on a silica column (AcOEt / NH 3 95: 5 then 1% MeOH) to give 46 mg (12%) of compound 61 and 283 mg (74%) of derivative 60.
  • this compound is dissolved in 2 ml of pyridine and 2 ml of anhydride acetic at 0 ° C. The reaction is stirred at room temperature for 48 h. The solvents are evaporated. The residue obtained is taken up in CH 2 CI 2 and washed twice with water. The organic phase obtained is dried over MgSO 4 , then evaporated under reduced pressure. The residue is purified by chromatography on a silica column (eluent: CH 2 CI 2 / AcOEt 7: 3) to give 235 mg (86%) of the derivative 76.
  • EXAMPLE 53 4- [5,8-Dimethoxy-3- (4-methoxyphenyl) -4-oxo-1, 4-dihydro-1 -quinolinyl] butanenitrile (compound 80) - CRL8421 and ⁇ [5,8-Dimethoxy- 3- (4-methoxyphenyl) -4- quinolyl] oxy ⁇ butanenitrile (compound 81) -CRL8501
  • EXAMPLE 57 3- [5,8-Dimethoxy-3- (4-methoxyphenyl) -4-oxo-1, 4-dihydro-1 - quinolinyljpentanenitrile (compound 86) - CRL8463 and ⁇ [5,8-Dimethoxy-3- (4-methoxyphenyl) -4-quinolyl] oxy ⁇ pentanenitrile (compound 87) -CRL8519

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP00958676A 1999-08-13 2000-08-11 Arzneimittel, welche 4-chinolonen enthalten zur behandlung von krebs Withdrawn EP1202971A2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9910492A FR2797444B1 (fr) 1999-08-13 1999-08-13 Compositions pharmaceutiques comprenant des 4-quinolones
FR9910492 1999-08-13
PCT/FR2000/002310 WO2001012607A2 (fr) 1999-08-13 2000-08-11 Compositions pharmaceutiques comprenant des 4-quinolones pour le traitement des cancers

Publications (1)

Publication Number Publication Date
EP1202971A2 true EP1202971A2 (de) 2002-05-08

Family

ID=9549145

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00958676A Withdrawn EP1202971A2 (de) 1999-08-13 2000-08-11 Arzneimittel, welche 4-chinolonen enthalten zur behandlung von krebs

Country Status (7)

Country Link
US (1) US6645983B1 (de)
EP (1) EP1202971A2 (de)
AU (1) AU7012200A (de)
CA (1) CA2381968A1 (de)
FR (1) FR2797444B1 (de)
IL (1) IL148106A0 (de)
WO (1) WO2001012607A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7345018B2 (en) * 2002-04-25 2008-03-18 Reception Aps Method of treating side effects induced by therapeutic agents
MXPA05010143A (es) * 2003-03-26 2006-03-17 Reception Aps Uso de compuestos para la prevencion de toxicidad celular inducida por farmaco.
EP2522670A1 (de) 2004-04-07 2012-11-14 Takeda Pharmaceutical Company Limited Heterozyklische CRF-Rezeptor-Antagonisten
TWI366565B (en) 2007-06-06 2012-06-21 Otsuka Pharma Co Ltd Quinolone compound and pharmaceutical composition
TWI472525B (zh) * 2008-12-05 2015-02-11 Otsuka Pharma Co Ltd 喹啉酮化合物及藥學組成物
WO2010064701A1 (ja) 2008-12-05 2010-06-10 大塚製薬株式会社 キノロン化合物を含む薬剤
US8598354B2 (en) 2008-12-05 2013-12-03 University Of South Florida Compounds having antiparasitic or anti-infectious activity
JP5769504B2 (ja) * 2010-06-04 2015-08-26 大塚製薬株式会社 医薬
CN105017145B (zh) * 2012-12-12 2017-12-05 王子厚 具有抗肿瘤活性的氯氧喹衍生物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994002145A2 (en) * 1992-07-22 1994-02-03 Genelabs Technologies, Inc. 2-aryl-4-quinolones as antitumor compounds
US5726184A (en) * 1995-05-19 1998-03-10 Vertex Pharmaceuticals Incorporated Tetralin compounds with improved MDR activity
GB9621757D0 (en) * 1996-10-18 1996-12-11 Ciba Geigy Ag Phenyl-substituted bicyclic heterocyclyl derivatives and their use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0112607A2 *

Also Published As

Publication number Publication date
WO2001012607A2 (fr) 2001-02-22
WO2001012607B1 (fr) 2001-11-22
US6645983B1 (en) 2003-11-11
FR2797444B1 (fr) 2003-02-07
WO2001012607A3 (fr) 2001-05-03
IL148106A0 (en) 2002-09-12
FR2797444A1 (fr) 2001-02-16
AU7012200A (en) 2001-03-13
CA2381968A1 (fr) 2001-02-22

Similar Documents

Publication Publication Date Title
EP1097138B1 (de) 2-chinolonen enthaltende arzneimittel
EP2046775B1 (de) N-(aminoheteroaryl)-1h-indol-2-carboxamid-derivate sowie deren herstellung und therapeutische anwendung
EP2829545B1 (de) Neue Phosphatderivate, ihr Herstellungsverfahren und pharmazeutische Zusammensetzungen, die sie enthalten
EP1841737B1 (de) N-(heteroaryl)-1h-indol-2-carbonsäureamidderivate und deren verwendung als vanilloid-trpv1-rezeptorliganden
CN101374833B (zh) 新型吡喃酮-吲哚衍生物及其制备方法
EP2658844B1 (de) Neue pyrimidinderivate, ihre herstellung und ihre pharmazeutische verwendung als akt (pkb)-phosphorylierungsinhibitoren
CA2917965C (fr) Nouveaux derives d'indole et de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CA2791490C (fr) Utilisation d'isoquinolones pour la preparation de medicaments, nouvelles isoquinolones et leur procede de synthese
WO2009077680A1 (fr) Dérivés de quinazolinedione, leur préparation et leurs applications thérapeutiques
CN102417483A (zh) 作为parp抑制剂的2-苯基-1h-苯并咪唑-4-甲酸酯衍生物
CN103360395B (zh) 一种吲哚咔唑类化合物及其制备方法和应用
WO2012160447A1 (en) 3, 5 -diphenyl- substituted pyrazolines for the treatment of cancer, proliferative, inflammatory or autoimmune diseases
EP1202971A2 (de) Arzneimittel, welche 4-chinolonen enthalten zur behandlung von krebs
EP0226508A1 (de) Indolo[3,2-c]chinolinderivate, Verfahren zu ihrer Herstellung und ihre Antitumorwirkung
MA29258B1 (fr) Nouveaux derives d'oximes heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP1373252A1 (de) Chemische derivate und ihre anwendung als antitelomerasemittel
CA3080116A1 (fr) Derives macrocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP0452204B1 (de) 3-Aminochroman-Derivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammensetzungen
JP2000309534A (ja) 血管新生阻害剤
WO2000003706A1 (fr) Composition therapeutique a base de flavonoïdes destinee a etre utilisee dans le traitement des tumeurs par des agents cytotoxiques
EP2917204A1 (de) 1-h-indol-3-carboxamidderivate und verwendung davon als p2y12-antagonisten
WO2005021518A1 (ja) 縮環化合物およびその用途
KR20220122978A (ko) 삼환식 화합물, 및 그의 제조 방법 및 그의 의학적 용도
WO1997005113A1 (fr) 4-aryl-thio-pyridin-2(1h)-ones, medicaments les contenant et leurs utilisations dans le traitement de maladies liees aux vih
CN108586425B (zh) 一种烷氧基联苯α,β-不饱和酰胺类化合物、其制备方法及医药用途

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020207

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

17Q First examination report despatched

Effective date: 20031126

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20060206